In a phase IIa randomized, double-blind trial (n=105) in patients with type 2 diabetes, nonalcoholic fatty liver disease, and moderate hypertriglyceridemia, 24 weeks of vupanorsen (20 mg once weekly or 40/80 mg every four weeks) was associated with decreases in TG by 36–53%, ANGPTL3 by 41–59%, apoC-III by 58%, remnant cholesterol by 38%, non–HDL-C by 18%, and apoB by 9%. This evidence concerns the gene ANGPTL3 and metabolic dysfunction-associated steatotic liver disease.